Indian journal of medical microbiology · 2026
Species distribution and antifungal susceptibility patterns of clinical Aspergillus isolates from a tertiary care center in India.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sudhaharan Sukanya, Pamidimukkala Umabala, Vinod Kumar Manthapuri, Verma Nikhi
Аннотация
INTRODUCTION: Aspergillus species causes numerous infections and results in increased mortality rates in patients with impaired immune systems. Given the rising resistance to antifungal agents, it is crucial to identify the species and perform antifungal susceptibility testing, thereby aiding clinicians in the effective management of patients. This study aims to identify the microbiological spectrum of Aspergillus spp. responsible for infections and their antifungal susceptibility profiles in our institution.
MATERIALS AND METHODS: This retrospective study was conducted from January 2024 to March 2025. Isolates of Aspergillus species acquired from various clinical specimens, including sputum, bronchoalveolar lavage fluid, ear canal secretions, and tissue samples, were included. The identification of Aspergillus spp. was conducted using conventional techniques and MALDI-TOF. Antifungal susceptibility testing (AFST) was conducted for voriconazole, posaconazole, itraconazole, and amphotericin B in accordance with CLSI guidelines, and the results were evaluated following CLSI protocols.
RESULTS: This study isolated 59 Aspergillus species from diverse clinical samples. Aspergillus flavus (34/59, 57.6%) was the most prevalent species isolated. In the current study, cryptic species were not identified. The majority of Aspergillus spp. were isolated from sputum (23/59, 38.9%). According to CLSI breakpoints, A. fumigatus exhibited susceptibility to voriconazole, while A. flavus, A. niger, and A. terreus, along with A. fumigatus, are classified as wild type based on the ECV for the tested antifungals.
CONCLUSION: A. flavus was the predominant species isolated in the current study. All Aspergillus species are susceptible to the tested antifungals.
MATERIALS AND METHODS: This retrospective study was conducted from January 2024 to March 2025. Isolates of Aspergillus species acquired from various clinical specimens, including sputum, bronchoalveolar lavage fluid, ear canal secretions, and tissue samples, were included. The identification of Aspergillus spp. was conducted using conventional techniques and MALDI-TOF. Antifungal susceptibility testing (AFST) was conducted for voriconazole, posaconazole, itraconazole, and amphotericin B in accordance with CLSI guidelines, and the results were evaluated following CLSI protocols.
RESULTS: This study isolated 59 Aspergillus species from diverse clinical samples. Aspergillus flavus (34/59, 57.6%) was the most prevalent species isolated. In the current study, cryptic species were not identified. The majority of Aspergillus spp. were isolated from sputum (23/59, 38.9%). According to CLSI breakpoints, A. fumigatus exhibited susceptibility to voriconazole, while A. flavus, A. niger, and A. terreus, along with A. fumigatus, are classified as wild type based on the ECV for the tested antifungals.
CONCLUSION: A. flavus was the predominant species isolated in the current study. All Aspergillus species are susceptible to the tested antifungals.